Terms: = Breast cancer AND PAM50 AND Staging
5 results:
1. Analysis of the association of HER-2 low carcinomas and pam50 assay in hormone receptor positive early-stage breast cancer.
Terán S; Alva M; Tolosa P; Rey-Cárdenas M; Madariaga A; Lema L; Ruano Y; Manso L; Ciruelos E; Sánchez-Bayona R
Breast; 2023 Oct; 71():42-46. PubMed ID: 37481795
[TBL] [Abstract] [Full Text] [Related]
2. Multicenter retrospective study on the use of Curebest™ 95GC breast for estrogen receptor-positive and node-negative early breast cancer.
Tsukamoto F; Arihiro K; Takahashi M; Ito KI; Ohsumi S; Takashima S; Oba T; Yoshida M; Kishi K; Yamagishi K; Kinoshita T
BMC Cancer; 2021 Oct; 21(1):1077. PubMed ID: 34610807
[TBL] [Abstract] [Full Text] [Related]
3. Superior breast cancer metastasis risk stratification using an epithelial-mesenchymal-amoeboid transition gene signature.
Emad A; Ray T; Jensen TW; Parat M; Natrajan R; Sinha S; Ray PS
Breast Cancer Res; 2020 Jul; 22(1):74. PubMed ID: 32641077
[TBL] [Abstract] [Full Text] [Related]
4. Multigene testing in breast cancer: What have we learned from the 21-gene recurrence score assay?
Turashvili G; Wen HY
Breast J; 2020 Jun; 26(6):1199-1207. PubMed ID: 32458521
[TBL] [Abstract] [Full Text] [Related]
5. Molecular Biological Features of Nottingham Histological Grade 3 breast cancers.
Takahashi H; Oshi M; Asaoka M; Yan L; Endo I; Takabe K
Ann Surg Oncol; 2020 Oct; 27(11):4475-4485. PubMed ID: 32436191
[TBL] [Abstract] [Full Text] [Related]
